MARIA BOTTAZZI to Cost-Benefit Analysis
This is a "connection" page, showing publications MARIA BOTTAZZI has written about Cost-Benefit Analysis.
Connection Strength
0.644
-
What Is the Economic Benefit of Annual COVID-19 Vaccination From the Adult Individual Perspective? J Infect Dis. 2024 Aug 16; 230(2):382-393.
Score: 0.183
-
Lives and Costs Saved by Expanding and Expediting Coronavirus Disease 2019 Vaccination. J Infect Dis. 2021 09 17; 224(6):938-948.
Score: 0.149
-
The Potential Economic Value of a Zika Vaccine for a Woman of Childbearing Age. Am J Prev Med. 2020 03; 58(3):370-377.
Score: 0.133
-
Vaccines against neglected tropical diseases: promising interventions to rescue the poorest populations in the Americas. Immunotherapy. 2014; 6(2):117-9.
Score: 0.088
-
The potential economic value of a therapeutic Chagas disease vaccine for pregnant women to prevent congenital transmission. Vaccine. 2020 04 03; 38(16):3261-3270.
Score: 0.034
-
Economic value of a therapeutic Chagas vaccine for indeterminate and Chagasic cardiomyopathy patients. Vaccine. 2019 06 19; 37(28):3704-3714.
Score: 0.032
-
Modeling the economic and epidemiologic impact of hookworm vaccine and mass drug administration (MDA) in Brazil, a high transmission setting. Vaccine. 2016 Apr 27; 34(19):2197-206.
Score: 0.026